IHC Panel for Liver Neoplasm Explained: Key Markers, Interpretation & Hepatocellular Carcinoma (India 2026) | लीवर न्यूप्लाज्म IHC पैनल गाइड
IHC Panel for Liver Neoplasm Explained: Key Markers, Interpretation & Hepatocellular Carcinoma (India 2026)
लीवर न्यूप्लाज्म IHC पैनल गाइड: HCC, Cholangiocarcinoma, Metastatic Tumours — Key Markers, Interpretation और Report Reading
A liver biopsy report has come back with an "IHC Panel" section listing markers like HepPar-1, Arginase-1, Glypican-3, CK7, CK19, CK20, AFP, CD10, and pCEA — and you are trying to understand what these results mean for diagnosis, prognosis, or treatment. Immunohistochemistry (IHC) panels for liver neoplasms are ordered by pathologists when a liver biopsy or surgical resection specimen cannot be definitively classified by routine haematoxylin and eosin (H&E) staining alone. India has a very high burden of hepatocellular carcinoma (HCC) — the most common primary liver malignancy — driven by endemic hepatitis B (see our HBsAg guide), hepatitis C, and the rapidly growing epidemic of NAFLD-related cirrhosis. The IHC panel determines: Is this tumour hepatocellular (from liver cells) or biliary (from bile duct cells)? Is this primary liver cancer or a metastasis from another organ? What is the likely primary tumour site if it is metastatic? This guide explains the most important liver IHC markers, how to read the pattern of positivity and negativity, and what the combination means for diagnosis.
For context on the underlying liver diseases that lead to HCC, see our guides on LFT (Liver Function Tests), SGOT/SGPT, and HBsAg (Hepatitis B). For reading lab and pathology reports generally, see our beginner's guide to blood test reports.
Liver biopsy report में IHC Panel आया — HepPar-1, Arginase-1, Glypican-3, CK7, CK19, CK20 जैसे markers — और समझ नहीं आ रहा। IHC panels तब order होते हैं जब routine H&E staining से tumour classify नहीं हो पाता। India में HCC (hepatocellular carcinoma) बहुत common — Hepatitis B, NAFLD-related cirrhosis के कारण। IHC panel बताता है: hepatocellular है या biliary? Primary liver cancer है या metastasis? यह guide सब explain करती है।Table of Contents / विषय सूची
- What Is IHC? Why Is It Done on Liver Biopsies?
- Hepatocellular Markers — HCC Panel
- Biliary / Cholangiocarcinoma Markers
- Markers for Metastatic Tumours in the Liver
- Complete Interpretation Table — HCC vs CCA vs Metastasis
- HCC in India — Epidemiology & IHC-Relevant Context
- What the IHC Report Means for Your Treatment
- Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
What Is IHC? Why Is It Done on Liver Biopsies?
Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific proteins (antigens) in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Each cell type in the body expresses a characteristic set of proteins depending on its origin, function, and differentiation state. By detecting which proteins are present or absent in tumour cells, pathologists can determine the cell of origin — which is the foundation of tumour classification, staging, prognosis, and treatment selection.
IHC (Immunohistochemistry) = specific antibodies से tissue में proteins detect करना। हर cell type characteristic proteins express करती है जो origin और differentiation पर depend करती है। Tumour cells में कौन से proteins present या absent हैं → cell of origin determine → tumour classification, staging, prognosis, treatment selection।- Poorly differentiated liver tumour on H&E: When tumour cells are so anaplastic (losing their normal characteristics) that their origin cannot be determined from morphology alone. A poorly differentiated HCC may look identical to a poorly differentiated adenocarcinoma from the colon or pancreas on H&E — IHC differentiates them.
- Unknown primary liver tumour: Patient presents with a liver mass on imaging — no known primary cancer elsewhere. IHC determines whether it is primary liver cancer (HCC or cholangiocarcinoma) or a metastasis from an occult primary tumour.
- Distinguishing HCC from Cholangiocarcinoma (CCA): Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) exists as a distinct entity. IHC is essential for distinguishing pure HCC from pure CCA from the combined tumour — with important implications for treatment.
- Diagnosing HCC in cirrhotic background: Early HCC nodules in a cirrhotic liver can be morphologically indistinguishable from dysplastic nodules or well-differentiated HCC on H&E — IHC (particularly Glypican-3, Glutamine Synthetase, and HSP70) helps confirm the diagnosis.
- Confirming metastatic site: A known colon, breast, or lung cancer patient develops a liver nodule — IHC confirms whether it is a new primary liver tumour or a metastasis from the known primary, which significantly changes prognosis and treatment.
- Research and molecular subtyping: IHC is used to classify HCC into molecular subtypes (proliferative vs non-proliferative), assess prognostic markers (Ki-67 proliferation index), and identify potential therapeutic targets (PD-L1, VEGF, FGFR for immunotherapy and targeted therapy eligibility).
Hepatocellular Markers — HCC Panel
| Marker | Expected Result in HCC | Staining Pattern | Clinical Significance |
|---|---|---|---|
| HepPar-1 (Hepatocyte Paraffin 1) | Positive (85–90% of HCC) | Granular cytoplasmic | The most widely used hepatocellular marker. Highly sensitive for well-differentiated HCC. Sensitivity falls in poorly differentiated HCC (50–60%). Can also be positive in hepatoid adenocarcinoma of the stomach and some adrenal cortical tumours. Always interpreted with other markers. |
| Arginase-1 | Positive (90–95% of HCC) | Nuclear and cytoplasmic | The most sensitive hepatocellular marker — superior to HepPar-1 in poorly differentiated HCC. Arginase-1 is a urea cycle enzyme expressed specifically in hepatocytes. Positive in well- and poorly differentiated HCC. Also positive in hepatoid carcinoma of other sites. Increasingly replacing HepPar-1 as first-line hepatocellular marker in many Indian reference labs. |
| Glypican-3 (GPC3) | Positive (70–80% of HCC) | Membranous / cytoplasmic | The most specific HCC diagnostic marker — virtually absent in normal hepatocytes, benign liver conditions, and hepatic adenoma. Critical for distinguishing early HCC from dysplastic nodules in cirrhotic liver. Also expressed in some testicular germ cell tumours (yolk sac tumour) — relevant cross-reactivity to note. |
| AFP (Alpha-Fetoprotein) | Positive (~40% of HCC) | Cytoplasmic | Lower sensitivity than HepPar-1 or Arginase-1 for IHC — AFP IHC is different from serum AFP (the blood tumour marker). When positive on IHC, it strongly supports HCC. Also positive in yolk sac tumours (germ cell tumours). Combines with Glypican-3 and HepPar-1 for HCC confirmation. |
| Glutamine Synthetase (GS) | Diffuse strong positive in HCC (focal weak in normal liver) |
Cytoplasmic | Excellent marker for distinguishing early HCC from high-grade dysplastic nodules. Normal liver shows weak centrilobular staining; HCC shows strong diffuse map-like staining. Part of the "HCC triple stain" (GS + Glypican-3 + HSP70) used in challenging needle biopsy cases of early HCC in cirrhotic background. |
| HSP70 (Heat Shock Protein 70) | Positive in HCC (nuclear + cytoplasmic) | Nuclear and cytoplasmic | Part of the "triple stain" for early HCC diagnosis. Sensitivity moderate (~65%); specificity high. Two or more of the triple stain positive (GS + GPC3 + HSP70) confirms HCC in ambiguous small nodule biopsies. |
| pCEA (polyclonal CEA) / CD10 | Canalicular pattern positive | Canalicular (linear membranous between cells) | The canalicular (bile canalicular) pattern of pCEA or CD10 staining is characteristic of hepatocellular differentiation — demonstrating the bile canaliculi that form between hepatocytes. Distinct from the cytoplasmic CEA positivity seen in adenocarcinomas. This canalicular pattern is highly specific for HCC when present. |
Biliary / Cholangiocarcinoma Markers
Cholangiocarcinoma (CCA) — cancer of the bile duct epithelium — is the second most common primary liver malignancy in India. IHC helps distinguish intrahepatic CCA from HCC and from metastatic adenocarcinoma (which can have overlapping morphology).
Cholangiocarcinoma (CCA) = bile duct epithelium का cancer — India में second most common primary liver malignancy। IHC: intrahepatic CCA को HCC और metastatic adenocarcinoma से distinguish करता है।| Marker | CCA Result | HCC Result | Clinical Significance |
|---|---|---|---|
| CK7 (Cytokeratin 7) | Positive (>90% of CCA) | Negative / focally positive | CK7 marks ductal/glandular epithelium. Strongly positive in CCA, negative or only focally positive in well-differentiated HCC. CK7 positivity in a liver tumour strongly argues against HCC and favours CCA or metastatic adenocarcinoma. |
| CK19 (Cytokeratin 19) | Positive (85–90% of CCA) | Negative (90% of HCC) | CK19 marks biliary progenitor cells. Highly specific for biliary/cholangiocytic differentiation. When positive in a primary liver tumour, strongly favours CCA over HCC. Importantly, CK19 positivity in HCC (the biliary phenotype of HCC) is associated with more aggressive behaviour, higher recurrence rate, and worse prognosis. |
| EpCAM (Epithelial Cell Adhesion Molecule) | Positive | Negative (most HCC) | EpCAM marks biliary/stem cell differentiation. When positive in HCC (EpCAM+ HCC), it is associated with hepatic progenitor cell origin, aggressive behaviour, high AFP, and resistance to sorafenib — an important prognostic and therapeutic subtype marker. |
| MUC1 / MUC5AC | Often positive (mucin expression) | Negative | Mucin markers support biliary/glandular differentiation. Positive MUC expression in a liver tumour supports CCA diagnosis. |
| S100P | Positive in CCA | Negative in HCC | Emerging marker for biliary differentiation. More specific for CCA than metastatic pancreatic adenocarcinoma in some studies. Used in conjunction with CK7/CK19. |
Markers for Metastatic Tumours in the Liver
| Suspected Primary Site | Key IHC Markers (Positive in Metastasis) | Notes & India Relevance |
|---|---|---|
| Colorectal Cancer | CK20 + (positive) CDX2 + (positive) CK7 − (negative) Villin + (variable) |
Most common metastatic tumour in liver globally. CDX2 is highly specific for intestinal differentiation. CK20+/CK7− pattern is classic for colorectal. Any CK20+/CK7− liver tumour in a patient above 40 must prompt colonoscopy if not done recently. |
| Gastric Cancer | CK7 + / CK20 variable CDX2 + (intestinal type) HER2 + (20–25%) GATA3 − (helps exclude breast) |
High incidence in India. HER2 IHC testing in gastric liver metastasis is critical for treatment — trastuzumab (Herceptin) targeted therapy for HER2+ gastric cancer significantly improves survival. HER2 positivity on IHC must be confirmed with FISH/ISH. |
| Breast Cancer | GATA3 + (highly sensitive) ER (Oestrogen Receptor) + PR (Progesterone Receptor) + HER2 + (20–25%) Mammaglobin + GCDFP-15 + |
Breast cancer liver metastasis is common in Indian women. GATA3 is the most sensitive marker for breast differentiation. ER/PR status and HER2 status from the liver biopsy guide treatment with hormone therapy (tamoxifen/aromatase inhibitors) or HER2-targeted therapy. |
| Lung Adenocarcinoma | TTF-1 (Thyroid Transcription Factor-1) + Napsin A + CK7 + CK20 − |
TTF-1 positivity in a CK7+/CK20− liver tumour strongly suggests lung adenocarcinoma origin. Napsin A is more specific than TTF-1. EGFR mutation testing and ALK/ROS1 IHC on liver biopsy material can guide targeted therapy. |
| Neuroendocrine Tumour (NET / Carcinoid) | Synaptophysin + (most sensitive) Chromogranin A + (most specific) CD56 + Ki-67 (grading index) |
Neuroendocrine liver metastases can closely mimic HCC on H&E. Synaptophysin and Chromogranin confirm neuroendocrine differentiation. Ki-67 index (percentage of tumour cells positive) determines WHO grade: G1 (<3%), G2 (3–20%), G3 (>20%) — with profound implications for treatment and prognosis. Liver NETs are treated differently from HCC (somatostatin analogues, PRRT, everolimus). |
| Pancreatic Adenocarcinoma | CK7 + CK20 variable MUC1 + CA19-9 + (IHC) SMAD4 (DPC4) loss S100P + |
SMAD4/DPC4 protein loss by IHC is seen in ~55% of pancreatic adenocarcinomas and is relatively specific for pancreatic origin when lost. Distinguishing pancreatic from biliary primary can be clinically important for resection planning. |
| Renal Cell Carcinoma (RCC) | PAX8 + (highly sensitive) RCC antigen + CD10 + (cytoplasmic, not canalicular) Vimentin + CK7 − (clear cell RCC) |
RCC liver metastasis can mimic clear cell HCC on H&E (both have clear cytoplasm). PAX8 is the most useful differentiator — positive in RCC, negative in HCC. CD10 in RCC is cytoplasmic (not the canalicular pattern seen in HCC). |
Complete Interpretation Table — HCC vs CCA vs Metastasis
| Marker | HCC | CCA | Colorectal Mets | Breast Mets | Lung Adeno Mets |
|---|---|---|---|---|---|
| HepPar-1 | + (85–90%) | − | − | − | − |
| Arginase-1 | + (90–95%) | − | − | − | − |
| Glypican-3 | + (70–80%) | − | − | − | − |
| CK7 | − (most HCC) | + (>90%) | − | + (most) | + |
| CK20 | − | − | + (classic) | − | − |
| CDX2 | − | − | + (highly specific) | − | − |
| GATA3 | − | − | − | + (highly sensitive) | − |
| TTF-1 | − | − | − | − | + (adenocarcinoma) |
| Synaptophysin / Chromogranin | − | − | − | − | − (unless SCLC) |
| PAX8 | − | − | − | − | − |
PAX8 positive = Renal cell carcinoma, thyroid, gynaecological (ovarian, endometrial) origin. CK19 = biliary (positive in CCA, negative in most HCC). ER/PR = breast primary. HER2 = breast or gastric primary. Always interpret IHC results with H&E morphology, clinical history, and imaging together.
Complete pattern: HCC = HepPar-1+/Arginase-1+/GPC3+/CK7−/CK20−। CCA = CK7+/CK19+/HepPar-1−। Colorectal = CK20+/CDX2+/CK7−। Breast = GATA3+/ER/PR/HER2। Lung adeno = TTF-1+/Napsin A+/CK7+/CK20−। NET = Synaptophysin+/Chromogranin+। RCC = PAX8+ (negative in HCC — key differentiator for clear cell lesions)। Pattern is diagnostic, no single marker alone।HCC in India — Epidemiology & IHC-Relevant Context
India is a high-endemicity country for Hepatitis B virus (HBV) — with an estimated 40 million HBsAg-positive individuals (see our HBsAg guide). HBV-related HCC constitutes approximately 50–60% of HCC cases in India. An important IHC consideration in HBV-related HCC: HBsAg (the hepatitis B surface antigen) can sometimes be detected directly in tumour cells by IHC using anti-HBsAg antibody, providing additional evidence of HBV aetiology. However, HBV-related HCC has no specific IHC marker profile that distinguishes it from non-HBV HCC — the hepatocellular IHC panel (HepPar-1, Arginase-1, Glypican-3) is identical regardless of the aetiology. Serum AFP is more frequently elevated in HBV-HCC than NASH-HCC. Patients with known HBV-related cirrhosis who undergo routine surveillance (6-monthly ultrasound + AFP) and are found to have a liver nodule — the IHC panel is critical for confirming HCC vs regenerative/dysplastic nodule when the nodule is below 2 cm and CEUS or MRI features are equivocal.
India में 40 million HBsAg-positive। HBV-related HCC 50–60%। HBsAg IHC tumour cells में detect करना possible। HBV-HCC का specific IHC profile नहीं — hepatocellular panel same (HepPar-1, Arginase-1, GPC3)। Known HBV cirrhosis + surveillance + <2 cm nodule equivocal on imaging → IHC confirm HCC vs dysplastic।NAFLD (Non-Alcoholic Fatty Liver Disease) — affecting 38–40% of Indian adults — is rapidly emerging as a significant HCC aetiology in India, particularly in patients without established cirrhosis (a proportion of NAFLD-HCC occurs in non-cirrhotic livers — an important point because these patients may not be undergoing routine HCC surveillance). NAFLD-related HCC tends to present at a slightly older age, more commonly in males, often at an advanced stage (because surveillance is not routinely performed in non-cirrhotic NAFLD patients), and with lower serum AFP levels compared to HBV-HCC. IHC implications: the hepatocellular marker panel is the same for NAFLD-HCC as for HBV-HCC. However, the background liver may show features of metabolic fatty liver (macrovesicular steatosis, mild lobular inflammation) that help identify the aetiological context. Glypican-3 positivity in a fatty background liver is particularly suspicious for HCC in an NAFLD context. See our HOMA-IR guide for the metabolic assessment of NAFLD patients.
NAFLD-HCC: 38–40% Indian adults में NAFLD। Non-cirrhotic liver में भी occur — surveillance नहीं होती → late presentation। Lower AFP। IHC panel same as HBV-HCC। Background: macrovesicular steatosis (NAFLD context identify करता है)। Glypican-3 positive in fatty liver background = HCC highly suspicious।Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) — a primary liver tumour containing both hepatocellular and cholangiocellular components — is a distinct WHO-recognised entity that is being increasingly diagnosed in India as IHC panels become more widely available at referral pathology centres. The incidence of cHCC-CCA in India may be higher than previously recognised — partly because, in the past, many of these tumours were classified as either HCC or CCA based on the dominant component, without the IHC confirmation that would have revealed the mixed nature. IHC of cHCC-CCA: the tumour shows focal positivity for both hepatocellular markers (HepPar-1, Arginase-1 — in the HCC component) AND biliary markers (CK7, CK19 — in the CCA component), within the same specimen. The proportion of each component determines the dominant IHC profile. Clinical significance: cHCC-CCA has a worse prognosis than pure HCC, is less responsive to sorafenib-based therapy, and requires different surgical and medical management than either pure HCC or pure CCA.
Combined HCC-CCA (cHCC-CCA): WHO-recognised entity। India में IHC panels available होने से increasingly diagnosed। Same specimen में: HCC component (HepPar-1+, Arginase-1+) AND CCA component (CK7+, CK19+)। Pure HCC से worse prognosis, sorafenib less responsive। Surgical + medical management different।Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare but clinically important variant of HCC that typically affects younger patients (age 20–40) without underlying cirrhosis or HBV infection. It is characterised on H&E by large polygonal cells with abundant eosinophilic (pink) cytoplasm, prominent nucleoli, and surrounding fibrous lamellae (bands of dense collagen separating tumour cell plates). IHC of FL-HCC has a distinctive profile: positive for hepatocellular markers (HepPar-1, Arginase-1) — confirming hepatocellular origin; additionally characteristically positive for CD68 (a marker usually associated with macrophages, but expressed in FL-HCC due to the abundant mitochondria in the tumour cells) and CK7 (a biliary marker that is also positive in FL-HCC, distinguishing it from conventional HCC). The diagnosis of FL-HCC is further confirmed by FISH or IHC for DNAJB1-PRKACA fusion gene — the specific oncogenic driver of nearly all FL-HCC cases, now detectable in many Indian reference pathology centres. FL-HCC has a better prognosis than conventional HCC in surgically resectable cases.
Fibrolamellar HCC: young patients (20–40), no cirrhosis, no HBV। H&E: large eosinophilic cells + fibrous lamellae। IHC: HepPar-1+/Arginase-1+ (hepatocellular) + CD68+ (mitochondria-rich) + CK7+ (biliary marker atypically positive)। DNAJB1-PRKACA fusion gene = specific oncogenic driver — FISH/IHC से confirm। Better prognosis than conventional HCC if resectable।What the IHC Report Means for Your Treatment
- Confirmed HCC (HepPar-1+, Arginase-1+, Glypican-3+, CK7−): Treatment options in India depend on Barcelona Clinic Liver Cancer (BCLC) staging: Early (single nodule ≤3cm, Child-Pugh A) → surgical resection (curative intent) or ablation (RFA/microwave); Intermediate (multinodular, no vascular invasion) → TACE (Trans-Arterial Chemo-Embolisation); Advanced (vascular invasion or extrahepatic spread) → sorafenib/lenvatinib (tyrosine kinase inhibitors) or atezolizumab+bevacizumab (first-line immunotherapy now approved in India). Liver transplantation within Milan criteria (single ≤5 cm or up to 3 nodules ≤3 cm) is available at selected Indian centres.
- Confirmed CCA (CK7+, CK19+, HepPar-1−): Surgical resection (curative) if early and resectable. Gemcitabine + cisplatin chemotherapy for unresectable or metastatic CCA. Pemigatinib (FGFR2 inhibitor) for FGFR2 fusion-positive CCA — FGFR2 mutation testing by next-generation sequencing (NGS) or IHC should follow the CCA IHC diagnosis. IDH1 mutation testing also relevant for ivosidenib eligibility.
- Colorectal metastasis (CK20+, CDX2+): Systemic chemotherapy (FOLFOX, FOLFIRI ± bevacizumab or cetuximab). Surgical resection of liver metastases if limited and resectable. KRAS/RAS mutation testing on tissue guides EGFR antibody eligibility (cetuximab or panitumumab are only effective in RAS wild-type tumours).
- Breast metastasis (GATA3+, ER+): Hormone therapy (tamoxifen in premenopausal; aromatase inhibitors in postmenopausal); HER2+ → trastuzumab-based therapy. CDK4/6 inhibitors (palbociclib, ribociclib) for ER+/HER2− metastatic disease — now increasingly available in India.
- Neuroendocrine tumour (Synaptophysin+, Chromogranin+): Ki-67 index from IHC determines WHO grade and therefore treatment: G1/G2 well-differentiated NET → somatostatin analogues (octreotide, lanreotide) for symptom control; PRRT (Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE) for progressive G1/G2 NET — available at selected Indian centres (TATA Memorial Mumbai, AIIMS Delhi). G3 NEC → platinum-based chemotherapy.
✅ Book Liver Biopsy with IHC Panel — NABL-Accredited Reference Pathology Lab
IHC panels for liver neoplasms require specialised pathology processing — formalin fixation, paraffin embedding, microtomy, antibody staining, and expert pathologist interpretation. Always send liver biopsy specimens to NABL-accredited reference pathology labs with hepatopathology expertise. Ensure the clinical history, imaging findings, and serum AFP value are provided with the specimen:
Affiliate link: I may earn a small commission at no extra cost to you. IHC panels for liver neoplasms are performed at AIIMS, Tata Memorial Hospital, CMC Vellore, major government teaching hospitals, and at private NABL-accredited reference pathology labs (Metropolis, SRL, Thyrocare Advanced, and others) across India. Always have IHC results interpreted by a surgical oncologist, hepatologist, or oncologist alongside imaging (CT/MRI/CEUS), serum AFP, clinical history, and multidisciplinary team (MDT) input. IHC results alone are never sufficient to make a final cancer management decision.
IHC panels: AIIMS, Tata Memorial, CMC Vellore, major NABL labs पर available। Clinical history + imaging + serum AFP specimen के साथ भेजें। 5–7 working days results। Surgical oncologist, hepatologist, और MDT team के साथ interpret करवाएं — IHC alone = final management decision नहीं।Liver Health Support — Two Evidence-Based Resources
Two products supporting liver health in the context of chronic liver disease and cancer prevention — a comprehensive patient education book on reversing fatty liver (NAFLD, the leading modifiable precursor to HCC in India) and a curcumin supplement with high bioavailability (curcumin has extensive preclinical and emerging clinical evidence for hepatoprotective, anti-inflammatory, and anti-tumour properties relevant to the NAFLD-to-HCC continuum). These products support general liver health education and lifestyle modification — they are not treatments for HCC, CCA, or any liver malignancy. A confirmed liver tumour requires immediate oncologist and surgical evaluation. Never delay cancer treatment in favour of supplements. Always discuss any supplement with your oncologist before use during cancer treatment.
NAFLD (Non-Alcoholic Fatty Liver Disease) is the fastest-growing precursor to HCC in India — and unlike hepatitis B (now vaccine-preventable), NAFLD is entirely driven by modifiable diet and lifestyle factors. The progression from NAFLD → NASH → cirrhosis → HCC takes 15–30 years, and interrupting this trajectory at the NAFLD stage — by achieving 7–10% weight loss, adopting a low-glycaemic diet, and exercising regularly — can completely prevent progression in the majority of patients. This book by hepatologist Dr Kristin Kirkpatrick and liver specialist Dr Ibrahim Hanouneh provides a comprehensive, evidence-based programme for reversing fatty liver disease through diet, exercise, and targeted nutritional interventions. It translates the complex hepatology of NAFLD into actionable lifestyle guidance that is highly relevant for Indian urban patients given the high NAFLD prevalence (38–40%), the high-carbohydrate Indian staple diet, and the metabolic syndrome epidemic driving both NAFLD and HCC. Key content: the NAFLD-HCC connection explained; the liver-friendly eating plan; inflammatory foods to avoid; exercise prescriptions for fatty liver; and the role of gut health in liver disease. This book is educational and preventive — it does not treat diagnosed liver cancer. If liver cancer has been diagnosed, immediate specialist oncology care takes absolute priority over any lifestyle book.
NAFLD → NASH → Cirrhosis → HCC: 15–30 years। NAFLD stage पर intervention = HCC prevent। India में 38–40% adults में NAFLD। 7–10% weight loss + low-GI diet + exercise = progression reverse। यह book: NAFLD-HCC connection, liver-friendly diet, exercise, gut health। Educational/preventive — diagnosed liver cancer में immediate oncology care priority। Supplement या book cancer treatment replace नहीं। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Curcumin (the primary active polyphenol in turmeric, Curcuma longa) is one of the most extensively studied natural compounds for liver health, with robust preclinical evidence and emerging clinical data supporting hepatoprotective, anti-inflammatory, and anti-fibrotic properties across the NAFLD-to-HCC spectrum. The primary evidence base: multiple clinical trials (including Indian trials given turmeric's cultural prevalence) show curcumin supplementation reduces SGPT/ALT, SGOT/AST, and GGT in NAFLD patients; reduces hepatic fat on ultrasound assessment; and reduces inflammatory markers (hs-CRP, TNF-α) that drive NASH progression. In the oncological context, curcumin has demonstrated anti-tumour activity in HCC cell lines and animal models through inhibition of NF-κB, PI3K/AKT, and Wnt/β-catenin pathways — the same pathways targeted by emerging HCC therapies. Several early-phase clinical trials are evaluating curcumin as an adjunct to sorafenib in HCC. The major limitation of dietary turmeric for these benefits: standard turmeric has less than 5% curcumin by weight, and curcumin alone has very poor oral bioavailability (extensively metabolised in the gut before reaching systemic circulation). Carbamide Forte's formulation addresses this through two strategies: high curcuminoid content (95% standardised extract, delivering far more active compound per capsule than dietary turmeric) and co-administration with piperine (black pepper extract) — which inhibits UDP-glucuronosyltransferase and P-glycoprotein in the gut, increasing curcumin oral bioavailability by approximately 20-fold. Curcumin supplementation does not treat liver cancer. It is an adjunct lifestyle support measure for NAFLD/chronic liver disease risk reduction, to be discussed with a hepatologist before use during any cancer treatment. Always inform your oncologist if taking curcumin alongside chemotherapy or targeted therapy, as potential drug interactions at the cytochrome P450 level have been described.
Curcumin: NAFLD में SGPT, SGOT, GGT कम, hepatic fat कम, inflammation (hs-CRP, TNF-α) कम। Anti-tumour activity in HCC models (NF-κB, PI3K/AKT inhibit)। Clinical trials: sorafenib के साथ adjunct as explore। Dietary turmeric: <5% curcumin + poor bioavailability। Carbamide Forte: 95% standardised curcuminoids + piperine (bioavailability 20×)। Curcumin = liver cancer treatment नहीं। Cancer treatment के दौरान oncologist को inform करें (CYP450 interactions)। View on Amazon IndiaAffiliate link — small commission at no extra cost.
Related Tests / संबंधित जांचें
These blood tests are commonly ordered alongside or before liver biopsy and IHC in the liver tumour workup:
Liver biopsy और IHC के साथ या पहले ये blood tests liver tumour workup में order होते हैं:Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
HepPar-1 (Hepatocyte Paraffin 1) positive means the antibody has detected its target protein — carbamoyl-phosphate synthetase 1, a mitochondrial urea cycle enzyme — in the tumour cells, displaying as a granular brown staining pattern in the cytoplasm under the microscope. This protein is specifically expressed in hepatocytes (liver cells) but not in bile duct cells, tumour cells from other organs, or most other cell types. A positive HepPar-1 result strongly supports that the tumour is of hepatocellular origin — meaning it arose from liver cells (hepatocytes), consistent with a diagnosis of hepatocellular carcinoma (HCC) or, less commonly, hepatoid adenocarcinoma from the stomach or ovary. It is one of the most sensitive hepatocellular markers — positive in 85–90% of well- to moderately differentiated HCC. However, HepPar-1 alone is not sufficient to diagnose HCC — it must be interpreted alongside the complete panel (Arginase-1, Glypican-3, CK7, CK20) and with the H&E morphology, clinical context, imaging, and serum AFP.
उत्तर: HepPar-1 positive = tumour cells में carbamoyl-phosphate synthetase 1 detected = hepatocellular (liver cell) origin confirmed। HCC diagnosis strongly support। 85–90% well/moderately differentiated HCC में positive। अकेला diagnostic नहीं — complete panel + H&E + clinical context + imaging + AFP के साथ interpret।Glypican-3 (GPC3) positive means the antibody has detected this proteoglycan protein on the cell surface and in the cytoplasm of the tumour cells. Glypican-3 is the most specific IHC marker for hepatocellular carcinoma — it is absent in normal hepatocytes, absent in hepatic adenoma, absent in cirrhotic nodules and most regenerative nodules, and present in 70–80% of HCC. This makes Glypican-3 critically important for a specific diagnostic challenge very common in Indian practice: distinguishing early HCC from high-grade dysplastic nodules in a cirrhotic liver on a needle biopsy. Both can look morphologically similar on H&E, but Glypican-3 is positive in early HCC and typically negative in dysplastic nodules — making this the key marker that drives the diagnosis from "suspicious for HCC" to "confirmed HCC." Glypican-3 is also the target of a novel immunotherapy (GPC3-targeted T-cell therapy) currently in clinical trials — so GPC3 positivity may have future therapeutic relevance beyond diagnosis. It is also positive in some testicular germ cell tumours (yolk sac tumour) — relevant clinical context to consider.
उत्तर: Glypican-3 positive = HCC का most specific marker। Normal hepatocytes, hepatic adenoma, dysplastic nodules में absent। Early HCC में positive। Critical use: cirrhotic liver में early HCC vs dysplastic nodule — GPC3 positive = HCC confirmed। GPC3-targeted T-cell therapy clinical trials में। Testicular yolk sac tumour में भी positive (context note करें)।A liver tumour showing CK7 positive and HepPar-1 negative strongly suggests the tumour is not of hepatocellular origin — it is not HCC. CK7 marks ductal/glandular epithelium and is typically negative in HCC, while HepPar-1 (a hepatocellular marker) being negative further excludes HCC. This pattern directs diagnosis toward: cholangiocarcinoma (CCA) — intrahepatic bile duct cancer — which is CK7 positive and HepPar-1 negative; or metastatic adenocarcinoma from another organ (the liver is a very common site of metastasis). To distinguish between intrahepatic CCA and a metastasis, additional markers are essential: CK19 (positive in CCA, helps confirm biliary origin); CDX2 (intestinal — positive in colorectal primary); TTF-1 (lung adenocarcinoma); GATA3 (breast); PAX8 (kidney, gynaecological tumours); Synaptophysin/Chromogranin (neuroendocrine tumours). The clinical history (any known cancer elsewhere?) and imaging (any mass at the primary site?) are critical for directing the next IHC marker selection. This CK7+/HepPar-1− result is one of the most important patterns on the liver IHC panel — it immediately redirects clinical investigation away from HCC management protocols and toward the appropriate primary tumour site workup.
उत्तर: CK7+ / HepPar-1− = NOT HCC। Directs toward: Cholangiocarcinoma (CCA) → CK7+/CK19+/HepPar-1− या Metastatic adenocarcinoma। Differentiate: CDX2 (colorectal), TTF-1 (lung adeno), GATA3 (breast), PAX8 (kidney/gynaecological), Synaptophysin/Chromogranin (NET)। Clinical history + imaging direction के लिए critical। HCC management protocols से दूर → primary tumour site workup की तरफ।The "HCC triple stain" refers to the simultaneous use of three IHC markers — Glutamine Synthetase (GS), Glypican-3 (GPC3), and HSP70 (Heat Shock Protein 70) — to diagnose early HCC in the challenging setting of a cirrhotic liver. This panel was specifically developed to address the diagnostic problem of small hepatic nodules (typically less than 2 cm) in patients with cirrhosis who undergo surveillance: these small nodules can be very difficult to classify definitively as early HCC versus high-grade dysplastic nodule on H&E alone, and the distinction has major clinical implications (HCC → active treatment; dysplastic nodule → intensified surveillance only). The triple stain works by exploiting different biological characteristics of early HCC: GPC3 is upregulated specifically in HCC cells but absent in dysplastic hepatocytes; GS shows a distinctive diffuse "map-like" strong staining in HCC versus weak centrilobular staining in normal/dysplastic liver; HSP70 is upregulated in HCC from oxidative stress and oncogenic signalling. The diagnostic rule: two or more of the three markers positive = early HCC confirmed (sensitivity approximately 72–78%, specificity approximately 93–100%). All three negative = likely high-grade dysplastic nodule — continue surveillance. The triple stain is increasingly used at tertiary liver cancer centres in India (TATA Memorial, AIIMS, major gastroenterology centres) for needle biopsy diagnosis of small cirrhotic nodules.
उत्तर: Triple stain = Glutamine Synthetase + Glypican-3 + HSP70। Small (<2 cm) cirrhotic liver nodules में use। GPC3: HCC में upregulated, dysplastic में absent। GS: HCC में diffuse "map-like" strong (normal/dysplastic में weak centrilobular)। HSP70: HCC में upregulated। Rule: 2/3 positive = early HCC confirmed (sensitivity 72–78%, specificity 93–100%)। All 3 negative = high-grade dysplastic → surveillance। India में TATA Memorial, AIIMS पर increasingly used।Ki-67 is a nuclear protein expressed exclusively in proliferating (actively dividing) cells — cells in G1, S, G2, or M phase of the cell cycle, but not in resting (G0) cells. The Ki-67 IHC result is expressed as a percentage: the proportion of tumour cell nuclei showing positive brown staining. This "proliferation index" directly reflects how fast the tumour is growing. For liver tumours: in HCC, a high Ki-67 index (above 15–20%) correlates with more aggressive tumour behaviour, higher vascular invasion, faster growth, and worse prognosis — it is sometimes used as part of post-resection risk stratification. For neuroendocrine tumours (NETs) of the liver, Ki-67 is the primary grading marker: Ki-67 below 3% = Grade 1 (G1, low grade — indolent, long survival); Ki-67 3–20% = Grade 2 (G2, intermediate); Ki-67 above 20% = Grade 3 (G3, high grade — aggressive, may require chemotherapy rather than somatostatin analogues). The WHO grading of NETs is based entirely on Ki-67 index — making it the most clinically actionable single IHC marker on a neuroendocrine liver tumour biopsy report.
उत्तर: Ki-67 = proliferating cells में nuclear protein। % = proliferation index (कितनी fast tumour grow कर रही है)। HCC में: high Ki-67 (>15–20%) = more aggressive, vascular invasion, worse prognosis। Neuroendocrine tumours में: WHO grading का primary marker। <3% = G1 (indolent); 3–20% = G2; >20% = G3 (aggressive → chemotherapy)। NETs में single most clinically actionable IHC marker।- WHO Classification of Tumours — Digestive System (5th Edition): WHO 2019 Classification of Liver Tumours — Including HCC, CCA, and Combined HCC-CCA
- AASLD (American Association for the Study of Liver Diseases): AASLD Practice Guidelines — HCC Diagnosis and Management
- Indian Journal of Pathology & Microbiology — IHC in liver tumours: IJPM — Indian Pathology Literature on Liver Neoplasm IHC
⚠️ Medical Disclaimer / चिकित्सा अस्वीकरण
This article is for educational purposes only — it is intended to help patients, families, and medical students understand IHC panel reports for liver neoplasms. IHC results must always be interpreted by a qualified pathologist alongside H&E morphology, clinical history, imaging findings, serum AFP, and other relevant tests. IHC interpretation is a complex specialist skill — a positive or negative marker result in isolation is never sufficient for a definitive diagnosis. All cancer diagnoses and treatment decisions must be made by a multidisciplinary oncology team (surgical oncologist, hepatologist, medical oncologist, radiation oncologist, and pathologist) in the context of complete clinical information. Supplements such as curcumin are not treatments for liver cancer and must never replace or delay appropriate oncological treatment. If liver cancer has been diagnosed or is suspected, seek specialist oncological care immediately.
यह लेख केवल educational purpose के लिए है। IHC results को pathologist से H&E morphology, clinical history, imaging, AFP के साथ interpret करवाएं। Single marker positive/negative = definitive diagnosis नहीं। Cancer diagnosis और treatment decisions: Multidisciplinary team (surgical oncologist, hepatologist, medical oncologist, pathologist) द्वारा। Curcumin/supplements = liver cancer treatment नहीं — oncological care replace नहीं। Liver cancer diagnosed/suspected → immediate specialist care।
Comments
Post a Comment